Stockreport

Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference

Editas Medicine, Inc.  (EDIT) 
Last editas medicine, inc. earnings: 2/26 04:02 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.editasmedicine.com
PDF CAMBRIDGE, Mass., March 27, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medic [Read more]